Market Cap
US$372.1m
Last Updated
2020/05/25 03:22 UTC
Data Sources
Company Financials +
Executive Summary
MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development of various therapies for the treatment of cancer.
Rewards
Risk Analysis
Snowflake Analysis
Flawless balance sheet with high growth potential.
Share Price & News
How has MEI Pharma's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: MEIP's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
19.4%
MEIP
0.7%
US Biotechs
1.8%
US Market
1 Year Return
12.9%
MEIP
22.1%
US Biotechs
3.7%
US Market
Return vs Industry: MEIP underperformed the US Biotechs industry which returned 22.1% over the past year.
Return vs Market: MEIP exceeded the US Market which returned 3.7% over the past year.
Shareholder returns
| MEIP | Industry | Market | |
|---|---|---|---|
| 7 Day | 19.4% | 0.7% | 1.8% |
| 30 Day | 50.6% | 4.9% | 5.6% |
| 90 Day | 59.5% | 10.7% | -7.4% |
| 1 Year | 12.9%12.9% | 23.3%22.1% | 6.1%3.7% |
| 3 Year | 65.6%65.6% | 36.3%31.7% | 28.3%19.8% |
| 5 Year | 82.8%82.8% | -2.5%-8.3% | 52.4%35.1% |
Price Volatility Vs. Market
How volatile is MEI Pharma's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall St
US$9.08 - That's What Analysts Think MEI Pharma, Inc. (NASDAQ:MEIP) Is Worth After These Results3 weeks ago | Simply Wall St
Have Insiders Been Buying MEI Pharma, Inc. (NASDAQ:MEIP) Shares This Year?1 month ago | Simply Wall St
Should MEI Pharma (NASDAQ:MEIP) Be Disappointed With Their 63% Profit?Valuation
Is MEI Pharma undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: MEIP ($3.51) is trading below our estimate of fair value ($33.12)
Significantly Below Fair Value: MEIP is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: MEIP is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: MEIP is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate MEIP's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: MEIP is overvalued based on its PB Ratio (5x) compared to the US Biotechs industry average (3.8x).
Next Steps
Future Growth
How is MEI Pharma forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
59.4%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MEIP is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.2%).
Earnings vs Market: MEIP is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: MEIP's is expected to become profitable in the next 3 years.
Revenue vs Market: MEIP's revenue (56.3% per year) is forecast to grow faster than the US market (8.9% per year).
High Growth Revenue: MEIP's revenue (56.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if MEIP's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has MEI Pharma performed over the past 5 years?
-2.9%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: MEIP is currently unprofitable.
Growing Profit Margin: MEIP is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: MEIP is unprofitable, and losses have increased over the past 5 years at a rate of -2.9% per year.
Accelerating Growth: Unable to compare MEIP's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MEIP is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.5%).
Return on Equity
High ROE: MEIP has a negative Return on Equity (-32.87%), as it is currently unprofitable.
Next Steps
Financial Health
How is MEI Pharma's financial position?
Financial Position Analysis
Short Term Liabilities: MEIP's short term assets ($95.4M) exceed its short term liabilities ($10.3M).
Long Term Liabilities: MEIP's short term assets ($95.4M) exceed its long term liabilities ($11.9M).
Debt to Equity History and Analysis
Debt Level: MEIP is debt free.
Reducing Debt: MEIP has not had any debt for past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: MEIP has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: MEIP has sufficient cash runway for 2.1 years if free cash flow continues to reduce at historical rates of 9.3% each year.
Next Steps
Dividend
What is MEI Pharma's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate MEIP's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate MEIP's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if MEIP's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if MEIP's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of MEIP's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
4.9yrs
Average management tenure
CEO
Dan Gold (65yo)
10.08yrs
Tenure
US$1,854,414
Compensation
Dr. Daniel P. Gold, also known as Dan, Ph.D. has been the Chief Executive Officer and President of MEI Pharma, Inc. (Alternate Name: Marshall Edwards Inc.), a subsidiary of Novogen Limited since April 26, ...
CEO Compensation Analysis
Compensation vs Market: Dan's total compensation ($USD1.85M) is about average for companies of similar size in the US market ($USD2.29M).
Compensation vs Earnings: Dan's compensation has been consistent with company performance over the past year.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 10.08yrs | US$1.85m | 0.34% $1.3m | |
| CFO & Secretary | 3.08yrs | US$842.61k | 0.035% $131.6k | |
| COO & General Counsel | 1.83yrs | US$1.31m | 0.023% $84.6k | |
| Chief Medical Officer | 8.92yrs | US$674.28k | 0.032% $118.2k | |
| Vice President of IR & Corporate Communications | no data | no data | no data | |
| Senior Vice President of Regulatory Affairs | 5.58yrs | no data | no data | |
| Senior Vice President of Clinical Development | 4.17yrs | no data | no data |
4.9yrs
Average Tenure
59.5yo
Average Age
Experienced Management: MEIP's management team is considered experienced (4.9 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 10.08yrs | US$1.85m | 0.34% $1.3m | |
| Independent Non-Executive Director | 0.83yr | no data | no data | |
| Independent Non-Executive Director | 2.25yrs | US$158.94k | 0.059% $219.4k | |
| Independent Non-Executive Director | 6.92yrs | US$166.44k | no data | |
| Independent Non Executive Director | 5.42yrs | US$161.44k | no data | |
| Independent Non-Executive Chairman | 4.42yrs | US$183.94k | 0.014% $52.6k | |
| Independent Non-Executive Director | 7.25yrs | US$161.44k | 0.0094% $35.1k | |
| Independent Non-Executive Director | 8.58yrs | US$168.94k | 0.028% $103.9k | |
| Non-Executive Director | 0.083yr | no data | no data |
5.4yrs
Average Tenure
65yo
Average Age
Experienced Board: MEIP's board of directors are considered experienced (5.4 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 48.7%.
Top Shareholders
Company Information
MEI Pharma, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: MEI Pharma, Inc.
- Ticker: MEIP
- Exchange: NasdaqCM
- Founded: 2000
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$372.055m
- Shares outstanding: 106.00m
- Website: https://www.meipharma.com
Number of Employees
Location
- MEI Pharma, Inc.
- 3611 Valley Centre Drive
- Suite 500
- San Diego
- California
- 92130
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| MEIP | NasdaqCM (Nasdaq Capital Market) | Yes | Common Stock | US | USD | Dec 2003 |
| MMIA | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Dec 2003 |
| 0JW9 | LSE (London Stock Exchange) | Yes | Common Stock | GB | USD | Dec 2003 |
Biography
MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development of various therapies for the treatment of cancer. The company’s clinical drug candidate includes Pracinostat, an oral available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome. Its clinical development portfolio also includes ME-401, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with relapsed/refractory follicular lymphoma and B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase inhibitor for B-cell malignancies and AML. In addition, the company engages in the development of ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex for the treatment of HER2-negative breast cancer. MEI Pharma, Inc. has a license, development, and commercialization agreement with Helsinn Healthcare SA for the development, manufacture, and commercialization of Pracinostat; and a license agreement with Presage Biosciences, Inc. to develop, manufacture, and commercialize Voruciclib, a clinical-stage, oral, and selective cyclin-dependent kinase inhibitor, as well as related compounds. The company also has a license agreement with CyDex Pharmaceuticals, Inc. for Captisol to use with ME-344, which are isoflavone-based drug compounds; a clinical collaboration agreement with BeiGene, Ltd. to evaluate the safety and efficacy of ME-401 in combination with BeiGene’s zanubrutinib, an investigational BTK inhibitor for the treatment of patients with B-cell malignancies; and a license agreement with Kyowa Kirin Co., Ltd. for ME-401. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was founded in 2000 and is based in San Diego, California.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/05/25 03:22 |
| End of Day Share Price | 2020/05/22 00:00 |
| Earnings | 2020/03/31 |
| Annual Earnings | 2019/06/30 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.